Best pharmaceutical companies in Miami, FL

PL Developments, Inc. manufactures, packages, and distributes over-the-counter (OTC) pharmaceutical products and consumer healthcare goods. The company offers solid and liquid dose OTC products in the areas of analgesics, allergy, digestive, sleep/awake, cough/cold, and motion; and first aid products, electrolytes, nutrient and vitamin gummies, supplements, creams and lotions, nasal sprays, eye drops, smoking cessation products, and nutritional shakes. It also provides contract manufacturing and contract packaging services to major OTC and nutritional companies. The company offers its products through retail stores in the United States and internationally. PL Developments, Inc. was founded in 1988 and is based in Westbury, New York. It has manufacturing, packaging, distribution, and research facilities in Miami, Florida; Lynwood, California; Clinton and Duncan, South Carolina; and Westbury and Farmingdale, New York.

Husa Liquidating Corporation, formerly HearUSA, Inc., provides a range of hearing aids, with emphasis on digital technology along with assessment and evaluation of hearing. The Company operates in three segments: the Company-owned centers, the network ...

Sanofi US is part of a leading global healthcare company that discovers, develops, produces and markets innovative therapies to help protect health and enhance people's lives. Along with the other U.S. affiliates, Genzyme, Sanofi Pasteur, Merial and Chattem, they work to prevent and treat the diseases they know about today, as well as those they may face tomorrow. Sanofi US, with headquarters in Bridgewater, New Jersey, employs more than 16,900 professionals throughout the country.

Biorasi is a full-service global CRO that runs on speed and agility. Our award-winning team accelerates your clinical trials to successful completion.

MD Now is the largest and fastest growing independent provider of urgent care services in South Florida with locations conveniently located across Palm Beach, Broward and Miami-Dade counties. All of their clinics are open 8am - 8pm, 365 days per year, giving you easy access to care you can trust. Their patients are typically seen and treated in under an hour, without an appointment, making MD Now the ideal provider of the care you need when you need it the most. MD Now takes urgent care a step further, ensuring quality care for higher acuity patients by maintaining a licensed doctor onsite at all times. Their state-of-the-art licensed facilities have been awarded the Certified Urgent Care Center (Category 1) designation from the Urgent Care Association of America and are accredited by the American Academy of Urgent Care Medicine, both signifying MD Now's commitment to the highest level of quality care. MD Now costs a fraction of a trip to the emergency room or hospital-affiliated urgent care. The lower cost setting they provide results in significant savings to the overall healthcare system, in addition to lower copays, out-of-pocket expenses and self-pay rates for their patients. At MD Now, these savings will never come at the cost of quality care.

Gilead Palo Alto, Inc. develops and commercializes small molecule drugs for the treatment of cardiovascular diseases. It develops advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery. The company offers Ranexa (ranolazine extended-release tablets), which is used for the treatment of chronic angina; and Lexiscan (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI). Its products under clinical development comprise Tecadenoson, which is in Phase III clinical trials product for the potential reduction of rapid heart rate during acute atrial arrhythmias, and in Phase II clinical trials for acute atrial fibrillation; Adentri, a Phase III clinical studies product for heart failure; CVT-6883, a Phase I clinical trial product to treat cardiopulmonary diseases; and CVT-3619, a Phase I clinical studies drug for diabetes/metabolic syndrome. The company s products under preclinical trials include Tecadenoson for atrial fibrillation; CVT-10,216 to treat alcohol addicted patients; Late I for the treatment of coronary artery disease; A2A antagonist for chemical dependence; ABCA1/ApoA-I to treat atherosclerosis; and Drug-Eluting Stent Program for the treatment of restenosis. The company has collaborative partnerships with Biogen Idec Inc.; Astellas Pharma, Inc.; Menarini Group; and Roche Palo Alto LLC. Gilead Palo Alto, Inc. was formerly known as CV Therapeutics, Inc. and changed its name to Gilead Palo Alto, Inc. in January 2009. The company was incorporated in 1990 and is based in Foster City, California. As of April 14, 2009, Gilead Palo Alto, Inc. operates as a subsidiary of Gilead Sciences Inc.